Vieira Eric, Huwyler Jörg, Jolidon Synèse, Knoflach Frédéric, Mutel Vincent, Wichmann Jürgen
Pharma Division, Discovery Research, F. Hoffmann-La Roche Ltd, CH-4070 Basel, Switzerland.
Bioorg Med Chem Lett. 2009 Mar 15;19(6):1666-9. doi: 10.1016/j.bmcl.2009.01.108. Epub 2009 Feb 6.
Small molecule mGluR1 enhancers, which are 9H-xanthene-9-carboxylic acid [1,2,4]oxadiazol-3-yl- and (2H-tetrazol-5-yl)-amides, have been previously reported. Fluorinated 9H-xanthene-9-carboxylic acid oxazol-2-yl-amides with improved pharmacokinetic properties have been designed and synthesized as useful pharmacological tools for the study of the physiological roles mediated by mGlu1 receptors. The synthesis and the structure-activity relationship of this class of positive allosteric modulators of mGlu1 receptors will be discussed in detail.
小分子代谢型谷氨酸受体1(mGluR1)增强剂,即9H-呫吨-9-羧酸[1,2,4]恶二唑-3-基-和(2H-四唑-5-基)-酰胺,此前已有报道。具有改善药代动力学性质的氟化9H-呫吨-9-羧酸恶唑-2-基-酰胺已被设计并合成,作为研究由mGlu1受体介导的生理作用的有用药理学工具。将详细讨论这类mGlu1受体正向变构调节剂的合成及构效关系。